NCT07130929

Brief Summary

This study aims to evaluate the effectiveness of physiotherapy treatment combined with functional electrical stimulation (FES) in a small group of patients with severe acquired brain injury (SABI) of vascular origin and with a clinical and instrumental diagnosis of "Intensive Care Unit-Acquired Weakness" (ICU-AW). Functional electrical stimulation is a technology that uses electrical impulses, generated by an external device, to reactivate the neuromuscular system through electrodes applied to the skin. In functional electrical stimulation, this process is integrated into physiotherapy sessions, with the active involvement of the patient, through the performance of exercises with the assistance and supervision of the physiotherapist. The rationale behind this is to stimulate neuroplasticity processes by facilitating movement through the application of electrical stimuli and the active participation of the patient in performing a motor task, in an attempt to promote improvement in an impaired function. In particular, the objectives that will be pursued are: improvement of lower limb neuromyopathy assessed clinically using the Medical Research Council (MRC) scale, the Fugl-Meyer scale for lower limbs, the Short Physical Performance Battery (SPPB) scale, the assessment of active and passive Range Of Motion (ROM) of the main joints of the lower limb (hip, knee, ankle) and measured instrumentally by neurophysiological examination and ultrasound examination. After randomization, patients in the control arm will be treated with physiotherapy and speech therapy sessions as per the conventional protocol, and an additional 15 physiotherapy sessions lasting 60 minutes over a period of 5 weeks. Alternatively, patients in the experimental group will receive, in addition to conventional rehabilitation treatment, a treatment consisting of 15 physiotherapy sessions combined with FES lasting 60 minutes over a period of 5 weeks. At the end of the treatment period, baseline characteristics and clinical and instrumental outcome variables will be compared between the two groups using the chi-square test for dichotomous and categorical variables and the t-test for independent samples or the Mann-Whitney U test for continuous variables, depending on whether or not they are normally distributed. In all analyses, a p-value \<0.05 will be considered significant.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
10mo left

Started Sep 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress42%
Sep 2025Mar 2027

First Submitted

Initial submission to the registry

August 6, 2025

Completed
13 days until next milestone

First Posted

Study publicly available on registry

August 19, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

September 23, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 23, 2026

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 23, 2027

Last Updated

December 11, 2025

Status Verified

October 1, 2025

Enrollment Period

1 year

First QC Date

August 6, 2025

Last Update Submit

December 4, 2025

Conditions

Keywords

strokeIntensive Care Unit (ICU) acquired weakness (ICU - AW)Functional Electrical StimulationFESRehabilitation

Outcome Measures

Primary Outcomes (1)

  • Change in lower limb neuromyopathy assessed blindly compared to the treatment/control arm at the clinical level using the Medical Research Council (MRC) scale.

    From enrollment to the end of treatment at 5 weeks from T0 (T1) and from enrollment to the follow-up at 12 weeks from T0(T2).

Secondary Outcomes (7)

  • Change in the units of the scale "Fugl-Meyer scale for lower limbs".

    From enrollment to the end of treatment at 5 weeks (T1) and from enrollment to the follow-up at 12 weeks(T2).

  • Change in the units of the scale "the Short Physical Performance Battery (SPPB) scale".

    From enrollment to the end of treatment at 5 weeks from T0 (T1) and from enrollment to the follow-up at 12 weeks from T0(T2).

  • Change in the degrees of the active range of motion of the main joints of the lower limbs (hip, knee, ankle).

    From enrollment to the end of treatment at 5 weeks from T0 (T1) and from enrollment to the follow-up at 12 weeks from T0(T2).

  • Change in the degrees of passive range of motion of the main joints of the lower limbs (hip, knee, ankle).

    From enrollment to the end of treatment at 5 weeks from T0 (T1) and from enrollment to the follow-up at 12 weeks from T0(T2).

  • Change in the parameters recorded during the neurophysiological examination using electromyography.

    From enrollment to the end of treatment at 5 weeks (T1).

  • +2 more secondary outcomes

Study Arms (2)

Arm in treatment with conventional physiotherapy plus FES

EXPERIMENTAL
Other: Functional Electrical Stimulation

Arm in treatment with only conventional physiotherapy

ACTIVE COMPARATOR

conventional physiotherapy in an equivalent additional session (without FES).

Other: Conventional physiotherapy

Interventions

Physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb, associated with functional electrical stimulation.

Arm in treatment with conventional physiotherapy plus FES

Conventional physiotherapy exercises, selected from a group of active flexion-extension exercises, cycle ergometer, sit-to-stand exercises and a preparatory exercise for the gait pattern with hip flexion and subsequent loading on the lower limb.

Arm in treatment with only conventional physiotherapy

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of ischemic or hemorrhagic vascular GCA involving unilateral motor deficit \< 3 months;
  • Premorbid Modified Rankin Scale \<2;
  • Age \>18 years and \<80 years;
  • Level of Cognitive Functioning \> 4 for active participation in treatment.
  • MRC total sum score \<= 48 (range 0 -60) for clinical suspicion of ICU-AW
  • Clinical diagnosis of tetra/paraparesis of peripheral origin confirmed by neurophysiological examination;
  • Signature of informed consent by the patient or, if incapacitated, by their legal representative.

You may not qualify if:

  • Clinical cardio-respiratory or internal instability such as to prevent treatment;
  • History of previous comorbidity for ICU-AW;
  • Previous known chronic neuropathy;
  • Severe coagulopathy;
  • Skin integrity problems at the interface surfaces with the electrostimulator;
  • Epilepsy not controlled by medication;
  • Presence of implanted electronic devices;
  • Pregnancy or breastfeeding;
  • Severe spasticity with a score of \>3 on the modified Ashworth scale;
  • Treatment with botulinum toxin;
  • Recent malignant neoplasm;
  • Conditions that put you at risk for neuropathies, e.g., history of diabetes mellitus, renal failure, hepatic failure, vitamin deficiencies, chronic alcoholism, vasculitis, previous use of neurotoxic drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS-Fondazione Don Gnocchi

Florence, FI, 50143, Italy

RECRUITING

Related Publications (5)

  • Wong JN, Olson JL, Morhart MJ, Chan KM. Electrical stimulation enhances sensory recovery: a randomized controlled trial. Ann Neurol. 2015 Jun;77(6):996-1006. doi: 10.1002/ana.24397. Epub 2015 May 4.

    PMID: 25727139BACKGROUND
  • Cecatto RB, Maximino JR, Chadi G. Motor recovery and cortical plasticity after functional electrical stimulation in a rat model of focal stroke. Am J Phys Med Rehabil. 2014 Sep;93(9):791-800. doi: 10.1097/PHM.0000000000000104.

    PMID: 24800715BACKGROUND
  • Peckham PH, Knutson JS. Functional electrical stimulation for neuromuscular applications. Annu Rev Biomed Eng. 2005;7:327-60. doi: 10.1146/annurev.bioeng.6.040803.140103.

    PMID: 16004574BACKGROUND
  • Intiso D, DI Rienzo F, Fontana A, Tolfa M, Bartolo M, Copetti M. Functional outcome of critical illness polyneuropathy in patients affected by severe brain injury. Eur J Phys Rehabil Med. 2017 Dec;53(6):910-919. doi: 10.23736/S1973-9087.17.04595-6. Epub 2017 Apr 14.

    PMID: 28417610BACKGROUND
  • Hakiki B, Draghi F, Scarpino M, Portaccio E, Romoli A, Mannini A, Atzori T, Lolli F, Macchi C, Grippo A. Critical illness polyneuromyopathy: Functional impact after severe acquired brain injuries. Acta Neurol Scand. 2020 Dec;142(6):574-584. doi: 10.1111/ane.13324. Epub 2020 Aug 31.

    PMID: 32740902BACKGROUND

MeSH Terms

Conditions

Brain InjuriesStroke

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and InjuriesCerebrovascular DisordersVascular DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 6, 2025

First Posted

August 19, 2025

Study Start

September 23, 2025

Primary Completion (Estimated)

September 23, 2026

Study Completion (Estimated)

March 23, 2027

Last Updated

December 11, 2025

Record last verified: 2025-10

Locations